ライフサイエンスコーパス: CLABSI

1 CLABSI data reported to NHSN from 2009 to 2012 from adul

2 CLABSI incidence rates were compared using Poisson regre

3 CLABSIs remain a significant problem in neonatal and ped

4 ne bathing period, 55 infections occurred: 4 CLABSI, 21 CAUTI, 17 VAP, and 13 C difficile.

5 ol bathing period, 60 infections occurred: 4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile.

6 During 2009-2012, 4654 CLABSIs were reported to NHSN from 299 adult oncology un

7 ing this period there were a total of 10,866 CLABSI cases and 9,543,765 central line days.

8 profile, antimicrobial resistance rates, and CLABSI incidence rates per 1000 central line-days were c

9 The most common organisms causing CLABSI in oncology locations were coagulase-negative sta

10 one resistance was more common among E. coli CLABSI in oncology than nononcology locations (56.5% vs

11 eneralized linear mixed model regression for CLABSI events.

12 tive personnel, are at an increased risk for CLABSIs.

13 cantly associated with an increased risk for CLABSIs.

14 ociated with increased risk for reported ICU CLABSI.

15 h system and was associated with declines in CLABSI consistent with published clinical trial findings

16 ial lock solutions led to a 69% reduction in CLABSI rate (relative risk [RR], 0.31; 95% confidence in

17 rventions were associated with reductions in CLABSI rates in neonates and children by a half or more,

18 studied, affected the relative reduction in CLABSIs, which also remained significant among studies r

19 h have resulted in significant reductions in CLABSIs and their associated adverse outcomes.

20 No significant reductions in CLABSIs have been noted with the use of either.

21 e of hospital acquired conditions, including CLABSIs.

22 health care-associated infections including CLABSIs, CAUTIs, VAP, or C difficile.

23 ntral line-associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns

24 ntral line-associated bloodstream infection (CLABSI) with each other and as compared with simplified

25 tral line-associated bloodstream infections (CLABSIs) and (2) patients with community-onset pneumonia

26 tral line associated bloodstream infections (CLABSIs) are a common source of morbidity and mortality

27 tral line-associated bloodstream infections (CLABSIs) are not fully understood.

28 tral line-associated bloodstream infections (CLABSIs) in neonates and children.

29 tral line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (

30 tral line-associated bloodstream infections (CLABSIs), using National Healthcare Safety Network surve

31 tral line-associated bloodstream infections (CLABSIs), we performed a systematic search of PubMed, Em

32 Independent predictors of CLABSI late complications included intensive care unit (

33 The estimated rate of CLABSI decreased by 23.5% (95% confidence interval, 9.8%

34 Furthermore, rates of CLABSI were significantly higher in oncology compared to

35 solutions are effective in reducing risk of CLABSI, and this effect appears to be additive to tradit

36 al line insertion and maintenance bundles on CLABSI rates in neonatal and pediatric intensive care un

37 regression analysis at the hospital level on CLABSI-observed cases by ICUs in acute care hospitals (n

38 A IPs from different facilities to report on CLABSI using their usual surveillance methods.

39 CDC's National Healthcare Safety Network on CLABSIs in intensive care units (ICUs), at over 4,000 Me

40 sociated with mortality for either PNEUMO or CLABSI patients.

41 itical care networks to significantly reduce CLABSI rates.

42 Quality improvement interventions to reduce CLABSI are an important component of patient safety init

43 e data indicate a recent decline in reported CLABSI rates, likely secondary to changes in diagnostic

44 iated with an increased risk of ICU reported CLABSIs.

45 of 236 and 100 patients were included in the CLABSI and PNEUMO cohorts, respectively.

46 rds, classification was more consistent with CLABSI assigned in a proportion ranging from 36% to 42%

47 of patient records that 18 IPs reported with CLABSI ranged from 14% to 39% (overall mean, 28% with a

48 USA100 strain (P = .02), whereas those with CLABSI were more likely to die if they were older (P < .